Drug and Therapeutics Bulletin 1995;33:65-67; doi:10.1136/dtb.1995.33965
Copyright © 1995 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

New drugs for hyperprolactinaemia

Relevant BNF section: 6.7.1

In 1976 we heralded the introduction of bromocriptine (Parlodel - Sandoz) as "an important advance" for the treatment of patients with hyperprolactinaemia.1 Now two new drugs are available for treating hyperprolactinaemia; cabergoline ({blacktriangledown}Dostinex - Pharmacia) which the manufacturer claims offers "a significant advance in prolactin control" and quinagolide ({blacktriangledown}Norprolac - Sandoz) for which the claim is of a "significant advance in the therapy of hyperprolactinaemia". Do these newer products hold real advantages?






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1995 BMJ Publishing Group Ltd.